{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:03:07Z","timestamp":1761156187865},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>After the approval of alirocumab and evolocumab, the first two monoclonal antibodies (mAbs) targeting proprotein convertase subtilisin kexin type 9 (PCSK9), this review provides an update on recent PCSK9 inhibitors data and describes recommendations for the use before the results of the ongoing cardiovascular endpoint trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>New studies and complementary analysis of phase III trials have consistently shown that alirocumab and evolocumab are highly effective in reducing LDL-cholesterol and to some extent lipoprotein (a). Some preliminary findings coming from exploratory and post-hoc analyses of the longer-term safety phase III trials and meta-analyses suggest that these mAbs can decrease the incidence of cardiovascular events. Whether or not mAbs targeting PCSK9 definitively reduce the incidence of cardiovascular events without safety concerns shall be demonstrated with the ongoing cardiovascular outcome trials. Waiting these outcome trials and given the high cost of these mAbs, groups of experts have proposed as priorities groups of patients with familial hypercholesterolemia and with atherosclerotic cardiovascular disease who have substantially elevated LDL-cholesterol on maximally tolerated statin\/ezetimibe therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Before the results of large cardiovascular outcome trials, PCSK9 inhibitors should be only used in some categories of patients with familial hypercholesterolemia and\/or with atherosclerotic cardiovascular disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000356","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T07:58:30Z","timestamp":1476777510000},"page":"597-604","source":"Crossref","is-referenced-by-count":11,"title":["Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience"],"prefix":"10.1097","volume":"27","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2015.06.008","article-title":"IMPROVE-IT and genetics reaffirm the causal role of LDL in cardiovascular disease","volume":"241","author":"Catapano","year":"2015","journal-title":"Atherosclerosis"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy \u2013 European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition. A new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9 \u2013 impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.vph.2014.05.011","article-title":"PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges","volume":"62","author":"Norata","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2014.07.004","article-title":"PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels","volume":"145","author":"Marais","year":"2015","journal-title":"Pharmacol Ther"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors; past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur Heart J"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease. A Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R23-20230917","first-page":"938","article-title":"Targeting PCSK9 for the treatment of hypercholesterolemia","volume":"10","author":"Hedrick","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.clinthera.2015.09.004","article-title":"Non-statin treatments for managing LDL cholesterol and their outcomes","volume":"37","author":"Turner","year":"2015","journal-title":"Clin Ther"},{"key":"R25-20230917","first-page":"1","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011\u20132015)","volume":"12","author":"Elbitar","year":"2016","journal-title":"Expert Opin Ther Pat"},{"issue":"(Suppl 3)","key":"R26-20230917","article-title":"ALN-PCSsc, an RNAi investigational agent that inhibits PCSK9 synthesis with the potential for effective bi-annual dosing: interim analysis","volume":"132","author":"Fitzgerald","year":"2015","journal-title":"Circulation"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"A1372","DOI":"10.1016\/S0735-1097(14)61372-3","article-title":"LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study","volume":"63","author":"Stein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines \u2013 an approach for long-term LDL-C management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS ONE"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1586\/14779072.2015.1111759","article-title":"An evaluation of alirocumab for the treatment of hypercholesterolemia","volume":"13","author":"Farnier","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehv707","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): a randomized, placebo-controlled phase 2 study","volume":"37","author":"Kastelein","year":"2016","journal-title":"Eur Heart J"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1194\/jlr.M061903","article-title":"Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody","volume":"56","author":"Schroeder","year":"2015","journal-title":"J Lipid Res"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2015.08.871","article-title":"Characterization of the first PCSK9 gain of function homozygote","volume":"66","author":"Alves","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutation and its specific treatment with alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2016.06.015","article-title":"Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol","volume":"251","author":"Lappeg\u00e5rd","year":"2016","journal-title":"Atherosclerosis"},{"key":"R37-20230917","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R43-20230917","doi-asserted-by":"crossref","DOI":"10.1161\/circ.132.suppl_3.17070","article-title":"Efficacy and safety of alirocumab: pooled analysis of 1048 individuals with diabetes mellitus from five placebo-controlled phase 3 studies of at least 52 weeks duration","volume":"132","author":"Ginsberg","year":"2015","journal-title":"Circulation"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins. ODYSSEY JAPAN randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.M033969","article-title":"PCSK9 SNP rs 11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population","volume":"54","author":"Postmus","year":"2013","journal-title":"J Lipid Res"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin\/kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study","volume":"117","author":"Blom","year":"2015","journal-title":"Circ Res"},{"key":"R53-20230917","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No evidence of effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0735-1097(16)31868-X","article-title":"Relationship between major adverse cardiovascular events and achieved low-density lipoprotein cholesterol levels in phase 3 ODYSSEY trials of alirocumab versus control","volume":"67","author":"Cannon","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R63-20230917","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw480","article-title":"ESC\/EAS Consensus Statement on PCSK9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","author":"Landmesser","year":"2016","journal-title":"Eur Heart J"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/eurheartj\/ehw010","article-title":"Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?","volume":"37","author":"Vuorio","year":"2016","journal-title":"Eur Heart J"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/eurheartj\/ehw098","article-title":"Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea","volume":"37","author":"Langslet","year":"2016","journal-title":"Eur Heart J"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels. Effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Saf"},{"key":"R70-20230917","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","article-title":"Role of PCSK9 beyond liver involvement","volume":"26","author":"Cariou","year":"2015","journal-title":"Curr Opin Lipidol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201612000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:09:35Z","timestamp":1694938175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201612000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000356","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}